Fundraising Fox

Eikonoklastes Therapeutics

Cincinnati, US · 2 known investors

Biotech

Founders & leadership

BH
Bruce HalprynExecutive

Board

SL
Samuel LeeBoard director
KM
Kenneth MorandBoard director
TF
Thomas FinnBoard director
JN
Joseph NolanBoard director
RJ
Robert JohnsonBoard director

Investors · 2

CincyTechCincinnati · $500K – $750K
JobsOhio VenturesColumbus

Reported raises · per SEC filings

Form D private placements

$25M disclosed across 6 of 7 rounds · 2020–2025

▶$13.6MraisedJul 2025 · 14 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas FinnDirector
  • Joseph NolanDirector
  • Robert JohnsonDirector
  • Samuel LeeExecutive Officer, Director
  • Bruce HalprynExecutive Officer, Director
  • Kenneth MorandDirector
Offering amount
$15.8M
Amount sold
$13.6M
First sale
Jul 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.4MraisedJun 2024 · 3 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Thomas FinnDirector
  • Neel PatelDirector
  • Meyer FrucherDirector
  • Kenneth MorandDirector
  • Bruce HalprynExecutive Officer, Director
  • Samuel LeeExecutive Officer, Director
Offering amount
$8M
Amount sold
$2.4M
First sale
Jun 2024
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2MraisedNov 2023 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Bruce HalprynExecutive Officer, Director
  • Thomas FinnDirector
  • Kenneth MorandDirector
  • Meyer FrucherDirector
Offering amount
$15M
Amount sold
$2M
First sale
Nov 2023
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.8MraisedJan 2022 · 1 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director
  • Kenneth MorandDirector
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
Offering amount
$7M
Amount sold
$2.8M
First sale
Dec 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3.2MraisedMay 2021 · 9 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • Bruce HalprynExecutive Officer, Director, Promoter
  • Thomas FinnDirector
  • Samuel LeeExecutive Officer, Director
  • Neel PatelDirector
  • Kenneth MorandDirector
Offering amount
$7M
Amount sold
$3.2M
First sale
Apr 2021
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2020 · 2 investors · Pharmaceuticals
Rule 506(b)
Officers, directors & promoters on the filing
  • SAMUEL LEEExecutive Officer, Director, Promoter
  • BRUCE HALPRYNExecutive Officer, Director, Promoter
Offering amount
$4M
Amount sold
$1.1M
First sale
Feb 2020
Incorporated
Corporation, Delaware, 2019
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Sell or Invest in Eikonoklastes Therapeutics Stock Pre-IPOnasdaqprivatemarket.com · Nov 2025Eikonoklastes Therapeutics has filed a notice of an exempt offering of securities to raise $15,764,780.00 in New Funding. - intelligence360intelligence360.news · Sep 2025CincyTech-backed Eikonoklastes Therapeutics gets FDA orphan drug designation for ALS treatment - Cincinnati Business Courierbizjournals.com · Nov 2022Eikonoklastes Closes Series A Fundingfinsmes.com · Jun 2021Eikonoklastes Closes Oversubscribed Series A Financing, Helping to Advance Immunotherapies Toward Clinical Trial Stagebusinesswire.com · Jun 2021Eikonoklastes Therapeutics Closes Oversubscribed Seed Financing to Advance Next-Generation Tissue Factor (TF) Immunotherapies With Initial Focus on Triple-Negative Breast Cancerbusinesswire.com · Jul 2020

Frequently asked questions

Who are Eikonoklastes Therapeutics's investors?
Eikonoklastes Therapeutics's investors include CincyTech, JobsOhio Ventures.
How much funding has Eikonoklastes Therapeutics raised?
Eikonoklastes Therapeutics has disclosed $25M raised across 6 of its 7 known rounds.
Where is Eikonoklastes Therapeutics headquartered?
Eikonoklastes Therapeutics is headquartered in Cincinnati, US.